GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avisa Diagnostics Inc (GREY:FOGCF) » Definitions » EPS (Diluted)

Avisa Diagnostics (Avisa Diagnostics) EPS (Diluted) : $0.16 (TTM As of Jun. 2021)


View and export this data going back to . Start your Free Trial

What is Avisa Diagnostics EPS (Diluted)?

Avisa Diagnostics's Earnings per Share (Diluted) for the three months ended in Jun. 2021 was $-0.14. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.16.

Avisa Diagnostics's EPS (Basic) for the three months ended in Jun. 2021 was $-0.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.16.

Avisa Diagnostics's EPS without NRI for the three months ended in Jun. 2021 was $-0.14. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.44.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Avisa Diagnostics EPS (Diluted) Historical Data

The historical data trend for Avisa Diagnostics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avisa Diagnostics EPS (Diluted) Chart

Avisa Diagnostics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.30 -0.02 -1.50 -0.84 -0.14

Avisa Diagnostics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.23 0.01 0.52 -0.14

Competitive Comparison of Avisa Diagnostics's EPS (Diluted)

For the Medical Devices subindustry, Avisa Diagnostics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avisa Diagnostics's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avisa Diagnostics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Avisa Diagnostics's PE Ratio falls into.



Avisa Diagnostics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Avisa Diagnostics's Diluted EPS for the fiscal year that ended in Dec. 2020 is calculated as

Diluted EPS (A: Dec. 2020 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.716-0)/5.224
=-0.14

Avisa Diagnostics's Diluted EPS for the quarter that ended in Jun. 2021 is calculated as

Diluted EPS (Q: Jun. 2021 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.531-0)/32.731
=-0.14

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avisa Diagnostics  (GREY:FOGCF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Avisa Diagnostics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Avisa Diagnostics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Avisa Diagnostics (Avisa Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
1660A Old Pecos Trail, Santa Fe, NM, USA, 87505
Avisa Diagnostics Inc is a clinical-stage medical device company developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials.